StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Alphagan/Combigan (brimonidine) by Quarter

Alphagan/Combigan (brimonidine) — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Alphagan/Combigan (brimonidine): -5.4% in Q4 2025, down 15.6 pts from a year earlier.

Latest, Q4 2025
-5.4%
Period ended Dec 31, 2025
Change on a year earlier
-15.6 pts
10.2% in Q4 2024
History
18 quarters
Since Q3 2021
Sources
18
Documents cited below

Where the Q4 2025 figure comes from

“|| Alphagan/Combigan | 18 | 36 | 54 | (54.8) | (4.5) | (30.5) | (5.4) | (30.9)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAlphagan/Combigan (brimonidine) — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q4 2025Dec 31, 2025-5.4%-15.6 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20254.7%+9.2 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-0.2%-20.7 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-15.4%-22.3 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202410.2%+0.4 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 2024-4.5%-21.8 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202420.5%+29.1 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 20246.9%-17.3 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 20239.8%+14.3 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202317.3%+14.4 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-8.6%-15.2 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202324.2%+18.7 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-4.5%-0.9 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 20222.9%+3.8 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 20226.6%–Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 20225.5%–Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗

Cite this data

StockData. (2026). AbbVie Alphagan/Combigan (brimonidine) (%), quarterly Q3 2021–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/alphagan-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.